Ltr Pharma
LTR Pharma is an Australian drug development company focused on men's health, specifically commercializing a rapid-onset, on-demand therapeutic nasal spray for erectile dysfunction. Their lead product, SPONTAN®, utilizes intranasal delivery technology of a PDE5 inhibitor, aiming for faster action and improved spontaneity compared to existing ED therapies.
Short position
Ltr Pharma (ASX:LTP) has 0.08% of its shares on issue reported as short positions as of 5 Oct 2026, or about 147,793 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.53% in July 2024. LTP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Ltr Pharma (LTP) short interest history
LTP Short Interest History
- 30-day change
- -0.01pp
- 90-day change
- -0.02pp
- 1-year change
- +0.05pp
- All-time high
- 0.53% (July 2024)
- All-time low
- 0.00% (December 2023)
Is LTP heavily shorted?
Not especially: 0.08% short interest is modest by ASX standards, ranking #463 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has LTP's short interest changed recently?
Over the past 30 days Ltr Pharma's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.08% of shares on issue.
What is the highest LTP's short interest has been?
Since 2023, Ltr Pharma's short interest peaked at 0.53% in July 2024 and bottomed at 0.00% in December 2023.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2023. See our methodology.